Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.

Journal: Cancer Cell

Published: 2020-03-13

DOI: 10.1016/j.ccell.2020.03.001

Affiliations: 18

Authors: 32

Go to article
Institutions Share
Department of Molecular Biology, UT Southwestern Medical Center, United States of America (USA) 0.26
Human Oncology and Pathogenesis Program (HOPP), MSKCC, United States of America (USA) 0.25
Weill Cornell Graduate School of Medical Sciences (WCGS, Cornell-MSKCC), United States of America (USA) 0.08
Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, United States of America (USA) 0.06
Cancer Biology and Genetics Program (CBG), MSKCC, United States of America (USA) 0.06
Molecular Pharmacology Program, MSKCC, United States of America (USA) 0.06
JAX Genomic Medicine, United States of America (USA) 0.03
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA) 0.03
Department of Medicine, MSKCC, United States of America (USA) 0.03
Center for Clinical and Translational Science (CCTS), The Rockefeller University, United States of America (USA) 0.03
Ludwig Institute for Cancer Research San Diego Branch, United States of America (USA) 0.03
Louis V. Gerstner Jr. Sloan Kettering Graduate School of Biomedical Sciences, MSKCC, United States of America (USA) 0.02
WorldQuant Initiative for Quantitative Prediction, United States of America (USA) 0.01
The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine (ICB), Cornell University, United States of America (USA) 0.01
Department of Physiology and Biophysics, Cornell University, United States of America (USA) 0.01
Hamon Center for Regenerative Science and Medicine, UT Southwestern Medical Center, United States of America (USA) 0.01
Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, United States of America (USA) 0.01
Howard Hughes Medical Institute (HHMI), United States of America (USA) 0

Return